Project Grant HT94252510723
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Texas M.D. Anderson Cancer Center received a $817,496 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, entitled "Targeting PRMT3-IGF2BP1 Axis-Mediated Epitranscriptomic Reprogramming as a Novel Therapeutic Strategy to Overcome Immunotherapy Resistance in ccRCC", will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
This Project Grant award, totaling $486,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports research conducted by the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to target PRMT5 in MTAP-loss melanoma. The project aims to transform health care for Service Members and the public through innovative and impactful cancer research, with a focus on...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
The federal Project Grant award of $735,799.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to the University of Texas MD Anderson Cancer Center to support the project "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS". The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public,...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The federal Project Grant award of $718,858.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award was granted to The University of Texas M.D. Anderson Cancer Center on February 15, 2025, with a planned completion date of February 14, 2028. As a leading academic cancer research institution, M.D....
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
The Department of the Army Medical Command awarded a $249,999 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. This three-year grant will fund research from September 2022 to August 2025 to revisit antiangiogenic therapy and target prostate cancer metabolism. The Military Medical Research and Development program, designated by CFDA #12.420, supports basic, applied, and advanced biomedical research with the goals...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,882,607.00 to The University of Texas M.D. Anderson Cancer Center to conduct research titled "LEVERAGING PROSTATE CANCERS' UNIQUE LIPID METABOLISM TO INDUCE THERAPEUTIC FERROPTOSIS." The grant period runs from March 15, 2025 to March 14, 2028. The research aims to transform healthcare for military service members, veterans, and the...